[Results of triethylene melanine therapy of Hodgkin's disease and of chronic myeloid leukemia; preliminary communication]

[Article in Undetermined language]

[Article in Undetermined language]

C E GARCIGA. Arch Cuba Cancerol. 1953 Jan-Jun.

. 1953 Jan-Jun;12(1-6):39-46.

No abstract available

Similar articles

The clinical use of triethylene melamine.
KRAVITZ SC, DIAMOND HD, CRAVER LF. KRAVITZ SC, et al. Blood. 1952 Jul;7(7):729-42. Blood. 1952. PMID: 14934758 No abstract available.
Myleran and triethylene melamine in the treatment of chronic granulocytic leukemia.
BETHELL FH. BETHELL FH. Ann N Y Acad Sci. 1958 Apr 24;68(3):996-1000. doi: 10.1111/j.1749-6632.1958.tb42655.x. Ann N Y Acad Sci. 1958. PMID: 13627746 No abstract available.
Unusual toxicity to triethylene melamine in a case of chronic myelogenous leukemia.
SLIPYAN A. SLIPYAN A. Ann Intern Med. 1953 Feb;38(2):331-5. doi: 10.7326/0003-4819-38-2-331. Ann Intern Med. 1953. PMID: 13017443 No abstract available.
TRIETHYLENE MELAMINE IN THE CONTROL OF HODGKIN'S DISEASE AND THE LEUKEMIAS. IV. CLINICAL REPORTS, 1959-62.
SAMPEY JR. SAMPEY JR. Am J Pharm Sci Support Public Health. 1963 Dec;135:451-7. Am J Pharm Sci Support Public Health. 1963. PMID: 14101404 Review. No abstract available.
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Takimoto Y, Tanabe O, Kuramoto A, Sasaki N, Nanba K. Takimoto Y, et al. Acta Haematol. 1994;92(2):97-100. doi: 10.1159/000204187. Acta Haematol. 1994. PMID: 7817711 Review.